SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-17-024645
Filing Date
2017-12-07
Accepted
2017-12-06 21:16:27
Documents
7
Period of Report
2017-12-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K - PRICING OF PUBLIC OFFERING vktx-8k_20171206.htm 8-K 35408
2 EX-1.1 vktx-ex11_6.htm EX-1.1 267721
3 EX-5.1 vktx-ex51_7.htm EX-5.1 10491
4 EX-99.1 vktx-ex991_8.htm EX-99.1 15018
5 GRAPHIC g2017120701431916550.jpg GRAPHIC 2494
6 GRAPHIC g2017120701431919851.jpg GRAPHIC 2494
7 GRAPHIC g2017120701431815969.jpg GRAPHIC 4119
  Complete submission text file 0001564590-17-024645.txt   342807
Mailing Address 12340 EL CAMINO REAL, SUITE 250 SAN DIEGO CA 92130
Business Address 12340 EL CAMINO REAL, SUITE 250 SAN DIEGO CA 92130 858-704-4660
Viking Therapeutics, Inc. (Filer) CIK: 0001607678 (see all company filings)

IRS No.: 461073877 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37355 | Film No.: 171243391
SIC: 2834 Pharmaceutical Preparations